Inhaled GM-CSF for Respiratory Virus-Associated Severe Pneumonia

• Status: Withdrawn
• Trial end date: 2019-05-01
• Target enrollment: 0
• Participant gender: All

Summary

This study will investigate the safety and efficacy of the administration of inhaled GM-CSF to patients with respiratory virus-associated pneumonia.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Milton S. Hershey Medical Center
• Treatments: Molgramostim; Sargramostim